Efficasy and safety of intrathecal injection of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS)

Phase 2

• Conditions: Amyotrophic lateral sclerosis.; Amyotrophic lateral sclerosis; G12.21

• Registration Number: IRCT20200828048551N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Patients diagnosed as definite or probable ALS disease according to EL Escorial criteria
ALSFRS-R more than 26
FVC more than 40%
age 25-70 years
Time passed since onset of the symptoms till inclusion be 3 years or less

Exclusion Criteria

Any major systemic disease
Any coexisting neurodegenerative disease
No other major pathology in brain or spinal cord
pregnancy or lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disability. Timepoint: 3 months. Method of measurement: ALSFRS-R.;Forced vital capacity. Timepoint: 3 months. Method of measurement: spirometry.;Side effects. Timepoint: 3 months. Method of measurement: Questionnaire.